doi:10.1016/j.addr.2006.09.019
Copyright © 2006 Elsevier B.V. All rights reserved.
Polymer genomics: An insight into pharmacology and toxicology of nanomedicines
aCenter for Drug Delivery and Nanomedicine and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Durham Research Center, 985830 Nebraska Medical Center, Omaha, Nebraska 68198-5830, USA
Received 13 September 2006;
accepted 29 September 2006.
Available online 6 October 2006.
References and further reading may be available for this article. To view references and further reading you must
purchase this article.
Abstract
Synthetic polymers and nanomaterials display selective phenotypic effects in cells and in the body signal transduction mechanisms involved in inflammation, differentiation, proliferation, and apoptosis. When physically mixed or covalently conjugated with cytotoxic agents, bacterial DNA or antigens, polymers can drastically alter specific genetically controlled responses to these agents. These effects, in part, result from cooperative interactions of polymers and nanomaterials with plasma cell membranes and trafficking of polymers and nanomaterials to intracellular organelles. Cells and whole organism responses to these materials can be phenotype or genotype dependent. In selected cases, polymer agents can bypass limitations to biological responses imposed by the genotype, for example, phenotypic correction of immune response by polyelectrolytes. Overall, these effects are relatively benign as they do not result in cytotoxicity or major toxicities in the body. Collectively, however, these studies support the need for assessing pharmacogenomic effects of polymer materials to maximize clinical outcomes and understand the pharmacological and toxicological effects of polymer formulations of biological agents, i.e. polymer genomics.
Keywords: Artificial vaccines; DNA microarray; Drug resistance; Signal transduction; Phenotype
Fig. 1. Examples of self-assembled nanomaterials with core-shell structure: (A) PEGylated liposomes produced from mixture of PEGylated and non-PEGylated lipids [8]; (B) polymer micelles with hydrophobic core formed by amphiphilic block copolymer [21]; (C) polyplex obtained by reacting DNA with cationic block/graft copolymer in presence of Pluronic® [178]; (D) polymer micelles with ionic core synthesized by condensing double hydrophilic block copolymer containing ionic block (poly (methacrylic acid) (PMA)) by Ca2+, cross-linking of the ionic blocks in the core of the formed micelles and removal of the condensing agent [33].
Fig. 2. Chemical structures of some polymers administered in the body.
Fig. 3. Scheme 1: A cooperative polyelectrolyte interchange reaction: At the first stage the free polyion (C) diffuses to the interpolyelectrolyte complex (AB); the chains reside together in the intermediate tertiary complex, while the oppositely charged polyion (B) migrates from polyion (A) to polyion (C); at the last stage the new interpolyelectrolyte complex (AC) is formed [91]. Scheme 2: Migration of polyions adsorbed at the oppositely charged particles: Polyelectrolyte adsorbed at the surface of untargeted particles (U) cannot dissociate into a solution; instead the particles migrate to each other forming a intermediate complex; the adsorbed polyion migrates to the surface of the targeted particles (T) where it is anchored through the ligand-receptor binding [95]. This mechanism was proposed for the recognition of specific immune cells by polyelectrolyte–antigen conjugates used as artificial vaccines as discussed in Section 5.
Fig. 4. Pluronic® block copolymers activate NF-κB signaling in cells: (A) Pluronic® affects NF-κB signaling presumably by interacting with cell plasma membrane; (B) this leads to rapid phosphorylation of I-kB accompanied by the release of the NF-κB [115]; (C) the released NF-κB translocates to the nucleus and activates transcription of the corresponding genes.
Fig. 5. Sensitization of MDR tumors by Pluronic® block copolymer: (A) Pluronic® binds with the cell membrane and inhibits Pgp ATPase; (B) Pluronic® also translocates inside cells and inhibits respiration in the mitochondria resulting in ATP depletion; (C) Pgp efflux pump shuts down; (D) the drug enters the cell and induces cytotoxic effect; (E) in the presence of Pluronic® the pro-apoptotic signaling in response to the drug is enhanced.